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When used in combination with certain chemotherapies, curcumin has been shown to increase apoptosis in several cancer cell 
lines. Here, we report the combined effects of curcumin and cinobufacini on human cervical carcinoma cells. The aim of this 
study was to examine whether curcumin could enhance apoptosis induced by cinobufacini. 3-(4,5-Dimethylthiazol-2-y1)-2,5- 
diphenytetrazolium bromide (MTT) assays revealed that the growth and proliferation of HeLa cells could be inhibited by 75% 
after a combined treatment of 25 μg/mL cinobufacini and 8 μg/mL curcumin. The combined treatment is 3 times more effective 
than treatment with 25 μg/mL cinobufacini alone. Annexin V-FITC/PI staining, morphological changes and immunofluorescence 
verified a significant enhancement in cinobufacini-induced apoptosis when cells were also exposed to curcumin. The data showed 
that the proportion of early apoptotic cells significantly increased from 15.43% in cells treated only with 25 μg/mL cinobufacini to 
49.2% in cells treated with 25 μg/mL cinobufacini and 8 μg/mL curcumin. Moreover, compared with treatment of only 25 μg/mL 
cinobufacini, ROS production increased 1.7-fold, the intracellular free Ca2+ concentration increased 1.5-fold, and the mitochon-
drial membrane potential decreased by 20% in the combined treatment. Simultaneously, the atomic force microscopy (AFM) re-
sults suggest that cells treated with a combination of cinobufacini and curcumin varied significantly in shape and ultrastructure. 
Collapsed cells with leaking cytoplasm, blebbing pores and emerging apoptotic bodies were prevalent. The nanoparticle size in-
creased from 70 nm when the cells were treated with 25 μg/mL cinobufacini to 190 nm when the cells were treated with 25 μg/mL 
cinobufacini and 8 μg/mL curcumin. The size increase resulted in the cell membrane becoming considerably rough. These results 
can improve our understanding of combination treatments. Specifically, the combination of cinobufacini and curcumin may po-
tentially find use as a novel cervical carcinoma treatment. Additionally, AFM is a powerful tool that can be used to explore cellu-
lar morphologies and ultrastructures. 
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Cervical carcinoma is the third most common cause of fe-
male mortality. A number of chemotherapeutic agents, in-
cluding cisplatin [1,2], paclitaxel [3], ifosfamide [4], and 
topotecan [5], have shown activity against advanced and 
metastatic cervical cancer. Compared with single-agent cis-
platin, cisplatin-based combination chemotherapy improves 
patient survival; however, this combination therapy shows 
greater toxicity and the improvements are only modest [6]. 
Therefore, there is a clear need for the development of new 
agents with novel mechanisms of action against this disease. 
In this study, we combined cinobufacini (CIN) and curcu-
min (CUR) to treat cervical carcinoma. 
Recently, several traditional Chinese medicines with an-
ti-tumor properties have attracted considerable interest as 
candidates for novel cancer therapeutics [7]. CIN is a water- 
soluble extract prepared from the skins of Bufo bufo gar-
garizans. Recent clinical studies have suggested that CIN, 
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used alone or in combination with other chemotherapeutic 
agents, has a profound effect on a number of cancers, par-
ticularly gastrointestinal tract carcinomas such as liver, 
pancreatic [8], and gastric cancers [9,10].  
CUR is a low molecular weight and natural polyphenolic 
compound isolated from the turmeric rhizome (Curcuma 
longa). CUR has been reported to harbor anti-oxidative, 
anti-inflammatory, anti-angiogenic, anti-proliferative, anti- 
tumor and wound healing properties [11–15]. CUR induces 
cancer cell apoptosis and shows low cytotoxicity in normal 
cells [16,17]. 
However, there are no reports on the combined effects of 
CIN and CUR on cervical cancer cells. The aim of this 
study was to examine whether CUR enhances CIN-induced 
apoptosis. We first used HeLa cervical cancer cell lines as a 
model to investigate CUR enhanced CIN-induced apoptosis. 
Simultaneously, an 3-(4,5-dimethylthiazol-2-y1)-2,5-di- 
phenytetrazolium bromide (MTT) assay, immunofluores-
cence, and flow cytometry were used to analyze the under-
lying molecular mechanisms of this enhancement. In recent 
years, attempts to understand the cellular, subcellular and 
molecular mechanical changes that occur throughout human 
disease states, including cancer, have garnered significant 
scientific interest. The plasma membrane, which is the 
boundary between a living cell and its environment, plays a 
very important role in cellular physiology. The plasma 
membrane protects the cell [18] and regulates cellular func-
tions, including the transport of nutrients [19,20]. Under-
standing the relationships between cellular ultrastructures, 
cellular and cytoskeletal mechanical properties, biological 
function and human health and disease states is a research 
area that has garnered much attention [21]. In this paper, we 
used AFM to visualize nanoscale changes in the subcellular 
ultrastructure resulting from chemical treatment. 
1  Materials and methods 
1.1  Reagents and cell culture 
CIN was obtained from Anhui Jinchan Biochemical Co. Ltd. 
(Huaibei, China). CUR was purchased from Tianjin Yongda 
Chemical Reagent Development Center (Tianjin, China). 
CUR was initially dissolved in dimethyl sulfoxide (DMSO) 
to obtain the desired concentrations. Fetal bovine serum, 
RPMI-1640, trypsin, and MTT kit was obtained from Gibco 
(New York, USA). An Annexin V-FITC/PI apoptosis detec-
tion kit, a Rhodamin 123 kit, a Fluo-3 AM kit, a 2′,7′-di- 
chlorofluorescein diacetate kit, a 5,5′,6,6′-tetrachloro-1,1′, 
3,3′-tetraethyl-imidacarbocyanine iodide (JC-1) kit, a 2-(4- 
amidinophenyl)-6-indo-119 lecarb-amidine dihydrochloride 
(DAPI) kit, and fluorescein isothiocyanate (FITC)-phal- 
loidin were purchased from Beyotime, China. All reagents 
used in the experiments were analytical grade. The ultrapure 
water used for all experiments was supplied by the cascade 
RO water purification system from Pall (New York, USA). 
The HeLa cells were purchased from the Life Science 
Research Institute of the Cell Resource Center in Shanghai, 
China. The cells were cultured in RPMI-1640 media sup-
plemented with 2 mmol/L glutamine, 10% fetal bovine se-
rum, 100 U/mL penicillin and 100 g/mL of streptomycin, 
and the cultures were grown at 37°C in a humidified at-
mosphere containing 5% CO2. When the cells grew to 
70%–80% confluence, they were passed according to a 1:3 
split. Once in the logarithmic growth phase, the cells were 
ready for the following experiments.  
1.2  MTT assay 
An MTT assay was employed to assess the toxicity effects 
of CIN alone or in combination with CUR on HeLa cells. 
Briefly, cells (6 ×104 cells/mL) were plated in 96-well plates. 
After 24 h, the cells were incubated with different concen-
trations of CIN (0, 6.25, 12.5, 25, 37.5 and 50 μg/mL) and 
either 4 μg/mL of CUR (CUR4) or 8 μg/mL of CUR (CUR8). 
The combined assay employed either 25 μg/mL CIN and  
4 μg/mL CUR (CIN25/CUR4) or 25 μg/mL CIN and 8 
μg/mL CUR (CIN25/CUR8); the cells were incubated with 
the agents for 48 h. Then, MTT was added to a final con-
centration of 10 μg/mL in each well for a 4-h incubation at 
37°C. The medium was then removed, and the cells were 
suspended in 150 μL of DMSO for 15 min. A spectropho-
tometer (TECAN, Switzer-210 land) was used to measure 
the absorbances at a wavelength of 570 nm. The cell inhibi-
tory rate was calculated using the following equation: Cell 
inhibitory rate = 1−(ODtreatment−ODblank)/(ODcontrol−ODblank)× 
100%. Each experiment was repeated at least three times. 
1.3  Determination of the apoptotic rate  
Apoptosis was quantified using an Annexin V-FITC apop-
tosis kit, which detects the surface exposure of phosphati-
dylserine in cells. Briefly, cells were seeded in 6-well plates 
at a density of 2×105 cells/mL and incubated for 24 h. Then, 
the cells were either treated with CIN only at doses of 0, 
6.25, 12.5, 25, or 37.5 μg/mL for 48 h or with CIN and 
CUR (CUR4 or CUR8) for 48 h. The cells were harvested, 
washed with ice-cold phosphate buffer saline (PBS), resus-
pended in 300 μL of binding buffer, and incubated with 5 
μL of FITC-labeled Annexin V and 5 μL of PI for 15 min at 
room temperature in the dark. Then, the samples were im-
mediately analyzed using a flow cytometer (BD Inc, New 
York, USA) at an excitation wavelength of 488 nm. 
1.4  Measurement of changes in the cytoskeleton and 
nucleus 
DAPI and FITC-phalloidin stains were used to observe the 
apoptotic cellular morphology and cytoskeletal rearrange-
ments. Briefly, cells at a concentration of 3×105 cells/mL 
were seeded in six-well plates and incubated for 24 h. Af-
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terwards, the cells were treated with CIN25 or with a com-
bination of CIN25 and CUR (CUR4 or CUR8) for 24 h. Then, 
the cells were fixed with 4% paraformaldehyde and stained 
successively with 50 μmol/L of DAPI for 5 min and      
1 μmol/L of FITC-phalloidin for 60 min in the dark at room 
temperature. Finally, the cells were washed with PBS. A 
laser scanning confocal microscope (Carl Zeiss, Germany) 
was used to image the nuclear morphology and the organi-
zation of the F-actin cytoskeleton. The amounts of F-actin 
in HeLa cells that were untreated, treated solely with CIN25, 
or treated with a combination of CIN25 and CUR were de-
termined by flow cytometry and actin-tracker green. Briefly, 
the cells, after being washed and harvested, were fixed by 
treatment with 4% paraformaldehyde for 15 min. The cells 
were incubated with actin-tracker green for 30 min, washed 
three times with PBS, and then suspended in PBS. The 
samples were immediately excited at 496 nm and analyzed 
with a flow cytometer (BD Inc, New York, USA). 
1.5  Atomic force microscopy 
Atomic force microscopy (AFM) was used to obtain topo-
graphic images of untreated cells, cells treated with CIN25, 
and with cells treated with a combination of CIN25 and CUR. 
Prior to use, the silicon nitride tips used in all AFM meas-
urements were irradiated with ultraviolet light to remove 
organic contaminants. The curvature radius of the tips was 
less than 10 nm, the elasticity coefficient was set at 2.8 N/m, 
and the oscillation frequency was set at 255 kHz. The sam-
ples were fixed by treatment with a 4% paraformaldehyde 
solution for 15 min after being monolayer-cultured, washed 
twice and dried at room temperature. Single-cell imaging 
experiments were performed on more than five cells, and 
each cell was scanned three times.  
1.6  Measurement of reactive oxygen species  
production 
Levels of intracellular reactive oxygen species (ROS) were 
determined by a Reactive Oxygen Species Assay Kit, which 
uses the staining probe DCFH-DA. DCFH-DA is a non- 
fluorescent probe that can freely penetrate the cell mem-
brane. In cells, DCFH is deacetylated by esterases to form 
2′,7′-dichlorofluorescin (DCFH), a non-fluorescent mole-
cule that reacts in the presence of ROS to form the fluores-
cent product 2′,7′-dichlorofluorescein (DCF). Briefly, cells 
were treated with CIN25 or with CIN25 in the presence    
of CUR (CUR4 or CUR8) for 24 h. The cells were then har-
vested, washed once with ice-cold PBS, and incubated  
with 10 μmol/L of DCFH-DA at 37°C for 30 min. After 
incubation with the fluorochrome, the cell culture was 
washed and resuspended in cold PBS. Then, to calculate the 
production of ROS, the fluorescence intensity was measured 
using flow cytometry; the flow cytometer was set at an ex-
citation wavelength of 488 nm and an emission wavelength 
of 525 nm. 
1.7  Detection of the intracellular free Ca2+  
concentration 
The fluorescent dye Fluo-3 AM can cross the cell mem-
brane and be converted into Fluo-3, which specifically re-
acts with Ca2+ to produce a molecule that strongly flu-
oresces. To detect changes in the free calcium level within 
the cytosol, both CIN-treated and untreated HeLa cells were 
incubated with Fluo-3 AM. The detailed procedure is as 
follows: HeLa cells that were untreated, treated with CIN25 
for 24 h, or treated with CIN25 in the presence of CUR 
(CUR4 or CUR8) for 24 h were collected, washed twice in 
PBS, and resuspended in Fluo-3 AM (5 μmol/L) for 30 min 
in the dark. The intracellular Ca2+ concentration was meas-
ured using a flow cytometer set at an excitation wavelength 
of 488 nm.  
1.8  Mitochondrial membrane potential measurement 
The MMP was monitored separately using two fluorescent 
dyes, rhodamin 123 and JC-1. The cells were harvested, 
washed, and resuspended in Rhodamine 123 (2 μmol/L) for 
30 min in the dark after being either treated with CIN25 for 
24 h or a combination of CIN25 and CUR for 24 hours. The 
fluorescence was measured by flow cytometry at an excita-
tion wavelength of 485 nm.  
In the normal cell, JC-1 accumulates and aggregates in 
the matrix of the mitochondria, forming J-aggregates and 
fluorescing bright red. In apoptotic cells, however, JC-1 
cannot aggregate in the matrix of the mitochondria due to 
the reduction of the MMP. Instead, JC-1 remains in the cy-
toplasm in its monomeric form and fluoresces green. The 
cells were seeded in confocal petri dishes after a 24-h 
treatment with CIN25 or a 24-h treatment with CIN25 in 
combination with CUR (CUR4 or CUR8). Then, 200 μL of 
JC-1 staining solution was added. The cells were incubated 
in this solution for 15 min. Then, the cells were washed 
with PBS and visualized directly under a laser scanning 
confocal microscope set to an excitation wavelength of 514 
nm. 
2  Results  
2.1  The cytotoxic effect of CIN alone and in  
combination with CUR 
To determine the ability of CUR to enhance the CIN-   
induced growth suppression of cells, cells were treated ei-
ther with CIN alone or with CIN and CUR. CUR signifi-
cantly enhances CIN-induced cell cytotoxicity when the 
cells are incubated for 48 h at 37°C. The results shown in 
Figure 1(a) revealed that after treatment for 48 h, CIN alone 
exhibited dose-dependent inhibitory effects on the viability  
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Figure 1  The cytotoxic effects of HeLa cells after a 48-h incubation with 
(a) CIN alone and (b) the combination of CIN25 and CUR as measured by 
MTT.  
of HeLa cells, and the inhibitory rate increased from 11% to 
56%. We adopted a CIN concentration of 25 g/mL for the 
following combined experiments. The CIN25/CUR4 combi-
nation treatment showed a growth inhibition rate of 64%, 
which is 2.5 times higher than that of CIN25 alone. The 
CIN25/CUR8 combination treatment showed a growth inhi-
bition rate of 75%, which is 3 times higher than that of 
CIN25 alone (Figure 1(b)). These data suggested that the 
CIN-induced growth suppression of HeLa cells could be 
strengthened in the presence of CUR.   
2.2  Apoptosis of HeLa cells induced by CIN alone and 
in combination with CUR 
Annexin V-FITC/PI staining was carried out to assess the 
extent and mode of HeLa cell death. The kit measures 
phosphatidylserine turnover from the inner to the outer lipid 
layer of the plasma membrane, an event typically associated 
with apoptosis. The proportions of early apoptotic cells 
were 8.05%, 10.62%, 15.43%, and 18.24% after HeLa cells 
were treated with CIN at concentrations of 6.25, 12.5, 25, 
37.5 and 50 μg/mL, respectively (Figure 2(a)–(c)). Fur-
thermore, Figure 2(d)–(f) reveal that compared with the 
CIN25 only treatment, the combined treatment significantly 
enhances the proportion of early apoptotic cells. The early 
apoptotic rates were 31.9% and 49.2% for CIN25/CUR4 and 
CIN25/CUR8, respectively. In contrast, the percentage of 
secondary necrosis, as measured by staining with both An-
nexin V/FITC and PI, did not significantly change. 
 
 
Figure 2  (Color online) Effect of CIN alone or combined with CUR on apoptosis as determined by flow cytometry. (a), (b) The representative apoptosis 
induced by CIN only. (d), (e) The representative apoptosis induced by the combination of CIN25 and CUR (CUR4 or CUR8). (c), (f) The statistical data for 
((a), (b)) and ((d), (e)) respectively.  
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2.3  Derangement of the cytoskeleton and damage to 
the nucleus 
Changes to cellular morphology were examined by specific 
staining after treatment with CIN alone or in combination 
with CUR. Specifically, the F-actin cytoskeleton was 
stained with Rhodamine-labeled phalloidin, and the nucleus 
was stained with DAPI. The cells were examined using a 
laser scanning confocal microscope (LSCM). Previous re-
ports provided evidence that cytoskeletal alterations could 
induce apoptosis as well as necrosis in a variety of models 
[22–26]. Thus, it was very important to investigate whether 
the combined treatment affected the arrangement of the cy-
toskeleton. In Figure 3(a) and (b), stains of control cells 
showed a generally homogeneous distribution of F-actin in 
the cytoplasm and intact, plump and uniform nuclei. After 
the 24-h treatment with CIN25, the F-actin aggregated and 
formed dot-like structures, and the nuclei presented as hip-
pocrepiform. Furthermore, the cytoskeletal networks com-
pletely disappeared. When treated with the CIN25/CUR8 
combination, the cells presented the typical morphology of 
apoptotic cells: The nuclei had broken, the chromatin was 
condensed and gathered at the periphery of the nuclear 
membrane, and the edges of the cells became blurred. Addi-
tionally, the cells appeared more widely distributed on the 
substrate. These observations indicate that the combination 
treatment significantly inhibited the proliferation of HeLa 
cells by changing the organization of the F-actin cytoskele-
ton and breaking the nucleus. Actin-tracker green was also 
employed to measure the amount of F-actin before and after 
treatment with CIN25 only or treatment with CIN25 and CUR 
(CUR4 or CUR8). Figure 3(c) shows that the fluorescent 
signal of the actin tracker in HeLa cells decreased more in 
the combined treatment than in the treatment with CIN25 
alone. The MFI of cells treated with CIN25 alone was 14670, 
while the MFI of cells treated with the CIN25/CUR8 combi-
nation decreased to 9339. Taken together, these results re-
vealed that the combined treatment was able to alter the 
organization of the cytoskeleton architecture by disrupting 
F-actin distribution and decreasing the expression of F-actin 
in HeLa cells more easily than the treatment with CIN25 
alone. 
2.4  Cell morphology and cell membrane ultrastructure 
characterization  
As a nondestructive cell surface imaging tool, AFM was 
used to observe a variety of changes in the surface mor-
phology and membrane ultrastructure of HeLa cells treated 




Figure 3  (Color online) Changes in the F-actin cytoskeleton and nucleus after treatment with CIN25 alone or in combination with CUR8. (a) The morphol-
ogy of cytoskeleton F-actin changes. (b) Variation in the morphology of the nucleus. (c) Alterations to F-actin expression. 
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Figure 4  (Color online) AFM topographic data of HeLa cells. (a)–(d) The topography of the control group, CIN25 group, CIN25/CUR4 group and 
CIN25/CUR8 group, respectively. (e)–(h) The 3-D modes corresponding to (a)–(d).   
shown in Figure 4, the control cells had a regular, long 
spindle-shaped morphology, and the nuclei were plump and 
elliptical. The cell tails were unrolled, and the cell surface 
was relatively smooth and intact (Figure 4(a) and (e)). After 
treatment with CIN25 alone, the cells shrunk, but the nuclei 
remained intact (Figure 2(b) and (f)). However, as shown in 
Figure 4(c) and (g), when the cells were also treated with 
the lower CUR concentration (CIN25/CUR4), the cells were 
deformed and shrunken. The edges of the cells became 
blurred, and the nuclei were no longer uniform. Upon in-
creasing the CUR concentration to 8 μg/mL (CIN25/CUR8) 
in the combined system, the cells varied significantly in size 
and shape. For example, cells collapsed, and the cytoplasm 
of many cells leaked. Additionally, blebbing pores and 
apoptotic bodies appeared over the cell surface (Figure 4(d) 
and (h)). These characteristics are indicative of apoptosis or 
necrosis.  
Moreover, AFM can provide nanoscale insight into ultra-
structural changes occurring in the topography of the cell 
membrane [28]. Figure 5 shows the cell surface ultrastruc-
ture of HeLa cells treated with CIN alone or in combination 
with CUR. The cell membrane architecture of the control 
cells (Figure 5 (a)) was homogeneous and presented a gran-
ular morphology with a surface particle size of approxi-
mately 45 nm. After CIN25 treatment alone, the surface of 
the cells became rough, and the nanoparticle size increased 
to 70 nm; the form became scattered. The visibly protruding 
particles are clusters of membrane proteins [29]. Further-
more, the cytoskeletal structure of the control cells present-
ed regular networks of F-actin, while the cytoskeleton net-
works disappeared and presented a gathered state after the 
combined treatments (shown in Figure 3). The nanoparticles 
on the cell membrane were aggregated and not a uniform 
size. The size increased to 150 and 190 nm for the CIN25/ 
CUR4 and CIN25/CUR8 combinations, respectively (Figure 
5(c) and (d)). Taken together, these morphological data re-
vealed dose-dependent morphological changes correspond-
ing to the combined treatment. The combined treatment 
mainly induced cell apoptosis. The morphological changes 
implied that some physiological changes could occur in 
membrane proteins, including the opening and closing of 
ion channels, the disruption of the ion channel structure, and 
alterations to the chemical composition of the outer mem-
brane [30]. The altered chemical composition of the outer 
membrane may have led to changes in the ultrastructure of 
the cytoskeleton and membrane surface. Further, these re-
sults provide morphological information about the com-
bined effects of induced HeLa cell toxicity (damage). The 
combined treatments affected the external structure of HeLa 
cells. This result might be related to F-actin disorganization, 
mitochondria-dependent apoptosis, or disruption of the nu-
cleus.  
2.5  Mitochondria-dependent apoptosis induced by  
enhancement of ROS overproduction and the free  
Ca2+ level 
Previous studies have shown that ROS, by-products of aer-
obic metabolism, play vital roles in intracellular signaling 
cascades [31,32]. Mitochondria are one of the major sources 
of intracellular ROS, and overproduction of ROS can trig-
ger stress pathways that ultimately lead to cell apoptosis 
[33]. High ROS levels can also cause cellular damage, de-
pending on the duration of ROS stress [34], and ROS can 
function as anti-tumor agents [35]. A novel cancer therapy 
strategy preferentially eradicates cancer cells by targeting 
the ROS stress-response pathway [36]. Thus, we investi-
gated changes in ROS production in cells before and after 
being treated with CIN or CIN in combination with CUR. 
Figure 6(a) and (b) show the data collected by the flow 
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Figure 5  (Color online) AFM ultrastructural data of HeLa cells before and after treatment with CIN25 only or treatment with CIN25 in combination with 
CUR (CUR4 or CUR8). (a) The topography mode (3 μm×3 μm). (b) The related 3-D images corresponding to (a). (c) The height profiles. (d) The grain diam-
eter histograms of the cell surface extracted from related images (a).  
 
Figure 6  (Color online) Flow cytometric analysis of ROS and intracellular free calcium (Ca2+) in HeLa cells treated with CIN only or CIN in combination 
with CUR. (a) Typical change of ROS determined by a DCFH-DA detection Kit. (b) Changes in ROS levels in HeLa cells treated with CIN25 for 24 h or with 
CIN25 and CUR (CUR4 or CUR8) for 24 h. (c) Typical changes in Ca
2+ levels determined by a Fluo-3 Detection Kit. (d) Changes in Ca2+ levels in HeLa cells 
treated solely with CIN25 for 24 h or with CIN25 and CUR (CUR4 or CUR8 ) for 24 h.  
cytometer and the mean fluorescence intensity (MFI), as 
dictated by ROS overproduction. CIN25 alone only slightly 
elevated the intracellular ROS levels: the MFI for CIN25 
treatment alone was 94.86, while the MFI for the control 
group was 69.20. Furthermore, the combination treatment 
yielded a significant increase in ROS production. The MFI 
values were 128.20 and 167.50 for the combined CIN25/ 
CUR4 and CIN25/CUR8 treatments, respectively (Figure 6(a) 
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and (b)). We have demonstrated that the combination treat-
ment triggers oxidative stress and that oxidative stress plays 
a major role in inducing apoptotic changes in HeLa cells. 
Increased intracellular Ca2+ concentration is also recog-
nized as an important marker of cell death and injury [37]. 
Thus, we measured the intensity of fluo-3 fluorescence, an 
indicator of the Ca2+ concentration. Figure 6(c) and (d) 
showed that the MFI of intracellular free Ca2+ was 109.60 
for the control group and 188.92 when the cells were treated 
with CIN25 alone. After CUR treatment, the cells displayed 
much higher Ca2+ concentrations; the MFI values were 
261.9 and 292.41 for the CIN25/CUR4 and CIN25/CUR8 
combination treatments, respectively. The results indicated 
that the increase in intracellular Ca2+ concentration was re-
lated to HeLa cell apoptosis. Cell signaling can be activated 
by a temporary increase in the cytoplasmic calcium level as 
a result of a calcium channel opening in the plasma mem-
brane or the endoplasmic reticulum [38]. The rise in the 
cytoplasmic Ca2+ concentration resulting from the combined 
treatment might be largely associated with membrane col-
lapse (Figure 4). Membrane collapse could promote the 
opening of Ca2+ channels in the cell membrane and the sub-
sequent influx of Ca2+.  
2.6  MMP loss induced by enhancement of ROS over-
production 
The loss of MMP could lead to cytochrome c release 
[39,40], a decrease in adenosine triphosphate (ATP) genera-
tion [41], the activation of caspases and initiation of apop-
totic cascades [42], all of which play important roles in the 
induction of cell death (necrosis or apoptosis). JC-1 staining 
was used to qualitatively confirm MMP disruption [43]. 
Rhodamine 123 was used to quantitatively detect the loss of 
MMP [44]. The JC-1 stain provides a distinct visual result, 
as red fluorescence is the indicator of higher MMP levels, 
while green fluorescence is the indicator of lower MMP 
levels. The combined treatment induced a dose-dependent 
fluorescent shift from red to green, indicating that the com-
bined treatment disrupted MMP in HeLa cells (Figure 7(a)). 
Moreover, the fluorescent intensity of Rhodamine 123 was 
reduced more by the combined treatment than by treatment 
with CIN25 alone. Figure 7(b) and (c) show that the MFI of 
the MMP was 103.10 for the control group and that the MFI 
of the MMP decreased to 83.62 upon treatment with CIN25 
alone. After CUR treatment, the MFI values were reduced 
to 38.46 and 16.68 for the combined CIN25/CUR4 and 
CIN25/CUR8 treatments, respectively. This information 
demonstrated that the combined treatment induces MMP 
disruption much more effectively than CIN25 treatment 
alone. The loss of MMP should play an important role in the 
apoptosis of HeLa cells.   
3  Discussion 
In this study, we first assessed the combined effects of CUR 
and CIN on human cervical carcinoma cells. The data show  
 
 
Figure 7  (Color online) The changes of membrane potential in HeLa cells treated with CIN alone or in combination with CUR. (a) LSCM images of 
changes to the MMP in the CIN25 only or combined treatment of HeLa cells stained with JC-1. (b) Flow cytometric analysis of typical changes to MMP 
determined by Rhodamine 123 staining. (c) Statistical data of changes to the MMP in HeLa cells treated for 24 h with CIN25 alone or in combination with 
CUR. 
2592 Liu L, et al.   Chin Sci Bull   July (2013) Vol.58 No.21 
that inhibition of viability and induction of apoptosis are 
more significant for the combined treatment than for treat-
ment with CIN alone.  
Moreover, the disorganization and depolymerization of 
the F-actin skeleton and the damage to the nucleus show 
that combination treatments induce apoptosis. The intracel-
lular oxidative stress resulting from the accumulation of 
ROS plays a key role in inducing apoptosis [45,46]. The 
increase of intracellular ROS by CIN is considered to be a 
major mechanism in CIN-induced cell injury and the prin-
cipal CIN treatment in cancer therapy [47]. ROS lead to free 
radical attack of membrane phospholipids and the loss of 
MMP, which releases inter-membrane proteins (such as 
cytochrome c) from the mitochondria. This process leads to 
the opening of a mitochondrial permeability transition pore 
and Ca2+ efflux from the cytoplasm [48,49]. In the presence 
of CUR, the increased ROS level suggests that the com-
bined treatment triggers the generation of oxidative stress. 
CUR could be a suitable chemical sensitizer of CIN-induced 
apoptosis. The MMP governs the electrochemical forces 
employed for ATP synthesis and other metabolic activities, 
including the maintenance of Ca2+ homeostasis within the 
mitochondria [50]. Due to the energy requirements of the 
different Ca2+ transport systems that control Ca2+ homes- 
tasis, the loss of MMP and the subsequent ATP depletion 
invariably result in the disruption of intracellular Ca2+ ho-
meostasis. These results demonstrate that the CUR en-
hancement of CIN-induced apoptosis in HeLa cells operates 
via ROS-dependent pathways. In this process, the ROS lev-
el and cytosolic free Ca2+ concentration increase, and the 
MMP decreases more significantly than after CIN treatment 
alone.  
Changes to the membrane structure have a direct influ-
ence on cellular function [51,52]. AFM morphological data 
indicate that the cell surface morphology changed from 
homogeneous to heterogenous. The AFM morphological 
data indicated shrinkage, blebbing, and the appearance of 
pores on the membrane. Furthermore, the ultrastructure of 
control cells presented regular networks of F-actin (shown 
in Figure 3), The cytoskeleton networks disappeared and 
presented a gathered state after the combined treatment 
(CIN25/CUR8) (Figure 3). CIN25-induced cells had a particle 
size of 70 nm. The particle size on the cell surface increased 
to 150 nm for CIN25/CUR4 and to 190 nm for CIN25/CUR8 
(Figure 5). This result suggested the altered chemical com-
position of the outer membrane or a reduction in the number 
of microvilli upon combined treatment with CIN and CUR.  
Furthermore, AFM enabled the detection of subtle (na-
noscale) changes to the structure of the cancer cell upon 
treatment with CIN25 alone or in combination with CUR. 
These results provided insight into the structure-function 
relationship of cell surfaces and yielded a more comprehen-
sive understanding of the drug-cell interactions during 
chemotherapy. These treatments disrupted the MMP and 
subsequently induced apoptosis. Moreover, these treatments 
were reflected in the ultrastructure of the cell surface.  
4  Conclusion  
This research provided detailed insights into potentially 
novel cervical carcinoma treatments. Moreover, this study 
demonstrated CUR’s enhancement of CIN-induced apopto-
sis. The results from this study could provide visual diag-
noses to early stage apoptosis in tumor cells in response to 
anti-cancer drugs. These studies also yield insight into drug- 
cell interactions. However, more research will be required 
to fully understand the specific anti-cancer mechanism of 
the enhancement of CIN-induced apoptosis by CUR.  
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